Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
DURAVYU
product2 mentionslast seen Oct 19, 2026
An investigational sustained-delivery intravitreal insert combining vorolanib with bioerodible Durasert E technology for treatment of retinal diseases.
Relationships 5
- DURAVYUapplies towet age-related macular degeneration treatment99% confidence2 sources
- DURAVYUapplies todiabetic macular edema treatment99% confidence2 sources
- DURAVYUcomposed ofvorolanib99% confidence2 sources
- DURAVYUcomposed ofDurasert E99% confidence2 sources
- EyePoint, Inc.developsDURAVYU99% confidence2 sources
Relationship
DURAVYUcomposed ofDurasert E
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 19, 2026EyePoint, Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 2.05: Cost Associated with Exit or Disposal Activities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
DURAVYU combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), with EyePoint's proprietary next-generation bioerodible Durasert E™
- filingSEC EDGAROct 19, 2026EyePoint, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
DURAVYU combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), with EyePoint's proprietary next-generation bioerodible Durasert E™